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Abstract
Autologous platelet concentrates are successfully adopted in a variety of medical fields to stimulate bone and soft tissue
regeneration. The rationale for their use consists in the delivery of a wide range of platelet-derived bioactive molecules that
promotes wound healing. In addition, antimicrobial properties of platelet concentrates have been pointed out. In this study,
the effect of the platelet concentration, of the activation step and of the presence of plasmatic components on the
antimicrobial activity of pure platelet-rich plasma was investigated against gram positive bacteria isolated from oral cavity.
The antibacterial activity, evaluated as the minimum inhibitory concentration, was determined through the microdilution
two-fold serial method. Results seem to suggest that the antimicrobial activity of platelet-rich plasma against Enterococcus
faecalis, Streptococcus agalactiae, Streptococcus oralis and Staphylococcus aureus is sustained by a co-operation between
plasma components and platelet-derived factors and that the activation of coagulation is a fundamental step. The findings
of this study may have practical implications in the modality of application of platelet concentrates.
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Introduction
Autologous platelet concentrates are successfully adopted in a
variety of medical fields to stimulate hard and soft tissue healing
and to control postoperative wound bleeding. The rationale for
their use consists in the delivery of a wide range of growth factors
and other bioactive molecules, stored in platelet a-granules and
released upon platelet activation, that promote migration,
proliferation and differentiation of the cells involved in wound
healing and regenerative processes [1,2]. In addition, anti-
inflammatory properties of platelet concentrates have been
pointed out, associated with a marked reduction of postoperative
pain and swelling [3–5].
Platelet concentrates are also believed to exhibit antimicrobial
properties. Recent studies have evaluated clinical and in vitro
antibacterial activity of platelet concentrates, showing inhibitory
effect against various microorganisms [6–20]. To date, the
components responsible for the antimicrobial activity of platelet
concentrates are poorly understood. In fact, platelet concentrates
are a complex mixture of platelets, leukocytes and plasma, and the
respective impact of the plasma and cellular components has not
been studied in detail yet.
Enterococcus faecalis is a microorganism associated with
different forms of periradicular disease, including primary extra-
radicular and post-treatment persistent infections [21]. Such
microorganism possesses the ability to survive the effects of root
canal treatment and persist as a pathogen in the root canals and
dentinal tubules of teeth. Implementing methods to effectively
eliminate E. faecalis from the dental apparatus is a challenge.
Streptococcus strains are consistently present in the human oral
cavity and are the major early colonizers of dental biofilm. Strains
of many species of oral streptococci are generally commensal in
humans. However, strains of other species, including those of S.
oralis and S. agalactiae, may be more commonly associated with
significant infections [22–23].
The oral cavity and oropharynx deserve greater attention as a
reservoir of Staphylococcus aureus. Studies suggested that the
presence of S. aureus in saliva was a significant risk factor for
aspiration pneumonia [24,25]. Oral S. aureus may also serve as a
reservoir for cross-infection to other patients, as well as health care
staff [26].
The aim of this study was to evaluate the antimicrobial effect of
different platelet concentrations, of the activation step and of the
presence of plasmatic components in a leukocyte-poor platelet
concentrate (pure platelet-rich plasma, P-PRP) against E. faecalis,
S. agalactiae, S. oralis and S. aureus strains isolated from oral
cavity.
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Materials and Methods
Donors
Blood samples were obtained from 20 healthy donors. All
subjects were in general good health condition (ASA 1-2). No
patient took antibiotics during the month before surgery, nor was
under anticoagulant or immunosuppressive therapy. Written
informed consent for participation in the study was obtained from
all patients. The present research was performed within the
guidelines of the Helsinki Declaration for biomedical research
involving human subjects. The study was approved by the Review
Board of the Galeazzi Orthopedic Institute.
Blood collection and production of platelet concentrates
Fresh human whole blood from donors was processed using a
laboratory centrifuge (Megafuge 1.0 R, Heraeus, Hanau, Ger-
many) to obtain P-PRP, following Anitua’s protocol [8]. Briefly,
peripheral blood (4.5 ml) from each donor was taken by
venipuncture into 5 ml blood-collecting tubes (Vacutainer,
Franklin Lakes, New Jersey, U.S.A.) with 3.8% (wt/vol) trisodium
citrate as anticoagulant. A pool was created with blood collected
from all patients. Blood was centrifuged at 580 g for 8 min at
room temperature. After centrifugation, three components were
obtained: red blood cells at the bottom of the tube; a thin layer of
leukocytes referred to as ‘‘buffy coat’’ in the middle; and plasma,
which contains most of the platelets, at the top. The plasma
fraction located above the red cell fraction, but not including the
buffy coat, was collected (P-PRP).
To evaluate the quality of the P-PRP produced, platelet and
leukocyte counts were performed using a hematology analyzer
(XE-2100, Sysmex Europe, Norderstedt, Germany). According to
Anitua et al., platelet concentration in P-PRP is at least twice the
concentration in whole blood, while leukocyte concentration is
consistently lower (,103 white blood cells/ml) [8].
Subsequently, three equal aliquots of P-PRP were collected and
processed as follows (Figure 1):
1) To prepare platelet-poor plasma (PPP), an aliquot of P-PRP
was centrifuged at 3000 g for 10 minutes. The supernatant
was recovered (PPP).
2) To obtain a pure platelet solution without plasmatic
components, an aliquot of P-PRP was centrifuged at 3000 g
for 10 minutes. The supernatant was removed, and the
platelet pellet was resuspended in a volume of phosphate
buffered saline (PBS; Sigma-Aldrich, St. Louis, Missouri,
U.S.A.) equal to that of the supernatant removed.
3) To further increase platelet concentration, an aliquot of P-
PRP was centrifuged at 3000 g for 10 minutes. The
supernatant was recovered, and the platelet pellet was
resuspended in half of the starting plasma volume. The
procedure was repeated twice in order to produce a platelet
concentration four times higher than that of P-PRP.
Platelet count was performed in the PPP, in the pure platelet
solution and in the concentrated P-PRP as a quality control.
Activation of platelet concentrates
P-PRP, PPP, the pure platelet solution and the concentrated P-
PRP were activated shortly before use. In order to initiate clotting
and trigger the release of platelet content, CaCl2 was added at a
final concentration of 4.5 mM.
Bacterial strains
Ten different strains of E. faecalis, S. agalactiae, S. oralis and S.
aureus respectively, isolated from oral clinical samples, were used.
Microorganisms were kept stored at 280uC until use. Bacterial
strains were previously identified by biochemical methods (Vitek 2
Compact, bioMe´rie´ux, Marcy l’Etoile, France) and confirmed by
DNA sequencing of 80 bp of the variable regions V1 and V3 of
the 16S rRNA gene by Pyrosequencing (PSQ96RA, Diatech, Jesi,
Italy). In addition, ATCC strains were used as controls. Before use,
strains were thawed and reconstituted in Brain Heart Infusion
broth (BHI; bioMe´rie´ux, Marcy l’Etoile, France) for E. faecalis
and S. aureus or BHI additioned with 5% defibrinated blood for
S. agalactiae and S. oralis for 24 hours at 37uC in proper
conditions.
Determination of antibacterial activity
The minimum inhibitory concentration (MIC), defined as the
lowest concentration of an antimicrobial substance that inhibits
the visible growth of a microorganism, was determined by broth
microdilution 2-fold serial method. After seeding on appropriate
medium (Trypticase Soy Agar or Columbia Blood Agar;
bioMe´rie´ux, Marcy l’Etoile, France), a suspension in growth
medium (BHI or BHI+5% defibrinated blood) was prepared for
each strain, with an optical density equal to 0.5 McFarland
(16108 CFU/ml). After obtaining a concentration of
16104 CFU/ml using appropriate dilutions, 20 ml of each
suspension were inoculated in a 96-wells microplate containing
180 ml of a serial 2-fold dilution (ranging from 1:2 to 1:2048) of the
material under evaluation. Both CaCl2 activated and non
activated samples were tested. Positive controls were performed
inoculating the microbial suspension in growth medium alone. In
order to assess that CaCl2 did not possess antimicrobial activity per
se, controls were performed inoculating microbial suspension in
growth medium additioned with CaCl2 at a final concentration of
4.5 mM. MIC values, corresponding to the lowest dilution
exhibiting no visible bacterial growth, were read visually after
24 hours of incubation at 37uC in proper conditions. The assay
was conducted in duplicate for each strain and, if the two MIC
values diverged by more than two dilutions, the assay was
repeated. MIC values were expressed as dilution from the initial
concentration. For each bacterial species and antimicrobial
combination, the MIC dilution mode and range were determined.
Results
Platelet and leukocyte counts
Platelet concentration in P-PRP pooled blood samples was 2.2
times higher than in whole blood (5656103 platelets/ml and
2526103 platelets/ml, respectively). Platelets in 2-fold and 4-fold
concentrated P-PRP were 1.8 and 3.6 times higher than in P-PRP
(9896103 platelets/ml and 20346103 platelets/ml, respectively).
Platelets were almost absent in PPP (,102 platelets/ml), while the
concentration of the pure platelet solution was almost equal to that
of P-PRP (5006103 platelets/ml). Pooled P-PRP was efficiently
leukocyte-depleted (,103 white blood cells/ml).
Determination of antibacterial activity
The MIC values observed for all strains tested ranged between
1:4 and 1:16. The MIC modal values for each bacterial species are
summarized in Table 1. Both P-PRP and PPP were able to inhibit
the growth of E. faecalis and S. aureus strains at a dilution of 1:8.
S. agalactiae and S. oralis strains seemed to be slightly more
susceptible to P-PRP than PPP, being inhibited by a dilution of
1:16 for P-PRP and by a dilution of 1:8 for P-PRP. However, no
Antimicrobial Properties of Autologus Platelet-Rich Plasma
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e107813
major differences (.two dilutions) were found between their MIC
values. Both 2-fold and 4-fold concentrated P-PRP were able to
inhibit the growth of all strains tested at a dilution of 1:16. In
contrast, platelets alone did not show any inhibitory effect at the
concentrations tested. Only activated samples displayed an
antibacterial activity, whereas non activated samples did not
exhibit any effect. CaCl2 per se did not show any antibacterial
activity. MIC values observed for ATCC bacterial strains fell into
the same dilution ranges as those of the corresponding clinical
isolates.
Discussion
The regenerative potential of platelet concentrates has been
explored considerably during the last two decades. On the contrary,
only few reports can be found about their antimicrobial effects in the
available literature. To date, the components responsible for the
antimicrobial activity of platelet concentrates remain poorly
understood. Several antimicrobial factors have been proposed,
including platelet antimicrobial proteins and peptides of the innate
immune defense, or platelet a-granules components, such as
complement and complement-binding proteins [17,18,27–31].
Direct interaction of platelets with microorganisms, participation
in antibody-dependent cell cytotoxicity, release of myeloperoxidase,
activation of the antioxidant responsive element and antigen-
specific immune response have also been suggested [15,32–33].
The role of leukocytes within platelet concentrates is a matter of
intense debate. Some authors have suggested that inclusion of
white blood cells in platelet concentrates may help to improve the
stability of the scaffold, increase the antimicrobial potential, and
help to regulate the inflammatory response [34]. On the contrary,
other authors suggested that an additional leukocyte content might
increase the inflammatory response at the site because of the
metalloproteases, pro-inflammatory proteases and acid hydrolases
secreted by white blood cells [35].
Our study was designed to elucidate which components in
leukocyte-poor platelet-rich plasma might inhibit bacteria. We
tested: 1) P-PRP, that is the formulation commonly used in our
clinics, 2) platelets resuspended in PBS, in order to determine the
role of platelets isolated from the plasmatic components, and 3)
PPP in order to define the antimicrobial role of plasma innate or
humoral immune response [36–37]. Moreover, we tested the
above-mentioned products before and after activation with CaCl2,
in order to evaluate their antimicrobial activity in the absence of
activation of coagulation and release of platelet granules content.
All materials tested were obtained from the same pool of donors
in order to limit the impact of individual donor variations.
Products were tested against four different species relevant to be
responsible of oral infections which have been previously shown to
be susceptible to platelet concentrates activity, such as E. faecalis,
S. agalactiae, S. oralis and S. aureus [7,8,13,15].
Activated P-PRP inhibited all strains, confirming the observa-
tions made in previous research works [7,8,13,15]. Activated PPP
showed the same activity of activated P-PRP. However, in the case
of S. oralis and S. agalactiae, a tendency to a greater susceptibility
for activated P-PRP was observed, with differences in MIC values
equal to 2 dilutions. This trend may be due to the release of
platelet-derived antimicrobial proteins, as suggested in a previous
work [38]. Finally, platelets alone did not show any antibacterial
activity. Taken together, these data seems to suggest that the
Figure 1. Experimental design of the study. The image illustrates the procedure used to obtain P-PRP, PPP, the pure platelet solution, 2-fold and
4-fold concentrated P-PRP. Starting from a whole blood pool, a P-PRP pool was obtained by centrifugation at 580 g for 8 minutes. Subsequently, P-
PRP pool was divided into three equal aliquots and processed in order to obtain the different materials under evaluation in this study.
doi:10.1371/journal.pone.0107813.g001
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antimicrobial activity of platelet concentrates against E. faecalis, S.
agalactiae, S. oralis and S. aureus is sustained by a co-operation of
plasma components and platelet-derived factors.
A recent study by Burnouf et al. tried to further understand
which components in platelet concentrates might bear the
antimicrobial activity, testing samples before and after heat
complement inactivation [10]. The absence of any bacterial
inhibition by any of the heat-treated plasma and platelet materials
supported the idea that the plasma complement (and/or other
heat-sensitive compounds) played the major role in the bacterio-
static properties of platelet concentrates. We tested heat-inactivat-
ed samples too (data not shown), confirming the results of Burnouf
et al. despite the differences in the experimental design of our
study (e.g. different protocol adopted for platelet concentrate
production, different method used to evaluate microbial suscep-
tibility, different bacterial strains tested, etc.). These results
strengthen the hypothesis of an implication of plasma components
in the antimicrobial activity of P-PRP.
We also evaluated the effect of platelet concentration on the
antimicrobial activity of platelet concentrate, comparing the
activity of 2-fold and 4-fold concentrated P-PRP. We observed
that all of them had a similar antibacterial activity against the
strains tested, independent of their platelet concentration. These
results are consistent with the findings of previous studies showing
no correlation between antimicrobial activity and the concentra-
tion of platelets in the blood and P-PRP [8,9].
In addition, we observed that only activated materials were able
to inhibit bacterial growth, suggesting that the activation of
coagulation is a fundamental step.
Despite the clinical relevance of these results in terms of
prevention of infections in surgery settings, future researches
should better investigate the potential practical implications of the
findings of this study as well as the modality of clinical application
of platelet concentrates.
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